Peripheral Vascular Disease Clinical Trial
Official title:
Decreasing Sedative Requirements for Peripheral Vascular Interventions Using Preoperative Guided Meditation
Verified date | December 2023 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this clinical trial is to test the feasibility of implementing a perioperative guided meditation program for patients undergoing peripheral vascular interventions that are performed under procedural sedation and analgesia.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | March 1, 2024 |
Est. primary completion date | December 11, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years of age or older - Undergoing an endovascular procedure for peripheral vascular disease - Anesthesia plan for procedural sedation and analgesia Exclusion Criteria: - Pre-existing psychiatric disorder such as anxiety, panic disorder, depression, psychosis, or bipolar disorder - Non-English speaking - Prior history of ipsilateral lower extremity amputation - Urgent or Emergent Surgery - Anesthesia plan for general anesthesia - Undergoing a hybrid procedure (simultaneous endovascular and open surgery) |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Southern New Hampshire Hospital | Nashua | New Hampshire |
United States | Newton Wellesley Hospital | Newton | Massachusetts |
United States | Salem Hospital | Salem | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | Agency for Healthcare Research and Quality (AHRQ) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of implementing preoperative guided meditation | Feasibility will be defined as >80% of the patients enrolled in the intervention arm having successfully completed both rounds of perioperative meditation. | Immediately before surgery | |
Secondary | Quality of Life - PROMIS-10 Global health. | The Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health survey is a patient-reported measure of health-related quality of life. The score range for the PROMIS-10 is from 0 to 20. Higher scores indicate higher quality of life, and thus are better. | Baseline | |
Secondary | Anxiety - STAI-6 | The State-Trait Anxiety Inventory (STAI) is a patient-reported measure of anxiety. The score range for the STAI-6 is from 6 to 24. Higher scores indicate higher anxiety, and thus are worse. | Preoperative (prior to meditation) and Postoperative (within 6 hours after surgery) | |
Secondary | Interoceptive attention - MAIA (Noticing sub scale) | The Multidimensional Assessment of Interoceptive Awareness (MAIA) is a patient-reported measure of interoceptive attention. The score range of the MAIA is from 0 to 5. Higher scores indicate higher awareness, and thus are better. | Preoperative (prior to meditation) and Postoperative (within 6 hours after surgery) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05335525 -
Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)
|
||
Active, not recruiting |
NCT01903044 -
Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating
|
Phase 1/Phase 2 | |
Completed |
NCT02271529 -
Zilver PTX Delivery System
|
N/A | |
Completed |
NCT02228564 -
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
|
N/A | |
Recruiting |
NCT02054871 -
RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty
|
N/A | |
Completed |
NCT00822172 -
Evaluation of Cilostazol in Combination With L-Carnitine
|
Phase 4 | |
Completed |
NCT00574782 -
Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)
|
N/A | |
Completed |
NCT00029991 -
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
|
Phase 1/Phase 2 | |
Completed |
NCT01355406 -
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
|
N/A | |
Recruiting |
NCT05804097 -
Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?
|
Phase 4 | |
Recruiting |
NCT03638115 -
The VaSecure BTK Study
|
N/A | |
Active, not recruiting |
NCT03241459 -
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
|
N/A | |
Active, not recruiting |
NCT01661231 -
Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe
|
N/A | |
Completed |
NCT01722877 -
JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
|
N/A | |
Completed |
NCT01444378 -
Absolute Pro® MOMENTUM™
|
N/A | |
Completed |
NCT00753337 -
The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study
|
N/A | |
Completed |
NCT00538226 -
Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg
|
Phase 1 | |
Completed |
NCT00593385 -
Atrium iCAST Iliac Stent Pivotal Study
|
N/A | |
Recruiting |
NCT00385385 -
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
|
Phase 2 | |
Completed |
NCT00392509 -
ALD-301 for Critical Limb Ischemia, Randomized Trial
|
Phase 1/Phase 2 |